Relmada Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RLMD research report →
About the company
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.
- CEO
- Sergio Traversa
- IPO
- 2014
- Employees
- 17
- HQ
- Coral Gables, FL, US
Price Chart
- Market Cap
- $658.71M
- P/E
- -5.66
- P/S
- 0.00
- P/B
- 2.49
- EV/EBITDA
- -11.02
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -71.22%
- ROIC
- -27.12%
- Revenue
- $0 · 0.00%
- Net Income
- $-57,385,163 · 28.25%
- EPS
- $-1.45 · 45.28%
- Op Income
- $-59,100,200
- FCF YoY
- 11.53%
- 52W High
- $8.00
- 52W Low
- $0.55
- 50D MA
- $6.91
- 200D MA
- $4.84
- Beta
- 0.41
- Avg Volume
- 1.57M
Get TickerSpark's AI analysis on RLMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 15, 25 | TRAVERSA SERGIO | buy | 27,500 |
| Dec 12, 25 | TRAVERSA SERGIO | other | 1,198,000 |
| Dec 12, 25 | Shenouda Maged | other | 828,000 |
| Dec 15, 25 | Shenouda Maged | buy | 11,665 |
| Dec 12, 25 | Ence Chuck | other | 828,000 |
| Dec 12, 25 | Fedeli Fabiana | other | 164,000 |
| Dec 12, 25 | GLASSPOOL JOHN | other | 164,000 |
| Dec 12, 25 | Kelly Paul Edward | other | 828,000 |
| Dec 12, 25 | CASAMENTO CHARLES J | other | 164,000 |
| Nov 5, 25 | Shenouda Maged | buy | 500,000 |
Our RLMD coverage
Recent articles, reports, and earnings notes.
No research on RLMD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RLMD report →Similar companies
Peers in the same neighborhood.